Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation

References

• Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–558. doi: 10.1016/S1083-8791(03)00287-8
   PubMed Web of Science ®Google Scholar
• Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88(10):4063–4071. doi: 10.1182/blood.V88.10.4063.bloodjournal88104063
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Schwender J, Heinz WJ, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica. 2011;96(1):142–149. doi: 10.3324/haematol.2010.029876
   PubMed Web of Science ®Google Scholar
• Reddy SM, Winston DJ, Territo MC, et al. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010;45(6):979–984. doi: 10.1038/bmt.2010.35
   PubMed Web of Science ®Google Scholar
• Maschke M, Kastrup O, Diener H C. CNS manifestations of cytomegalovirus infections: diagnosis and treatment. CNS Drugs. 2002;16(5):303–315. doi: 10.2165/00023210-200216050-00003
   PubMed Web of Science ®Google Scholar
• Mori T, Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol. 2010;91(4):588–595. doi: 10.1007/s12185-010-0569-x
   PubMed Web of Science ®Google Scholar
• Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood. 2003;101(2):463–465. doi: 10.1182/blood-2002-07-1982
   PubMed Web of Science ®Google Scholar
• Baldanti F, Lilleri D, Gerna G. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematol Oncol. 2008;26(3):123–130. doi: 10.1002/hon.856
   PubMed Web of Science ®Google Scholar
• Baldanti F, Gatti M, Furione M, et al. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. J Clin Microbiol. 2008;46(11):3672–3677. doi: 10.1128/JCM.00913-08
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Labirio M, et al. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis. 2008;40(1):68–70. doi: 10.1016/j.bcmd.2007.06.020
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Furione M, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood. 2007;110(7):2757–2760. doi: 10.1182/blood-2007-03-080820
   PubMed Web of Science ®Google Scholar
• Chou S, Ercolani RJ, Sahoo MK, et al. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother. 2014;58(8):4697–4702. doi: 10.1128/AAC.03214-14
   PubMed Web of Science ®Google Scholar
• Jain NA, Lu K, Ito S, et al. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. Cytotherapy. 2014;16(7):927–933. doi: 10.1016/j.jcyt.2014.02.010
   PubMed Web of Science ®Google Scholar
• Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986;40(3):281–286. doi: 10.1038/clpt.1986.177
   PubMed Web of Science ®Google Scholar
• Abu-Khader A, Krause S. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation – a comparison of different assays for the detection of cytomegalovirus-specific T cells. Eur J Haematol. 2013;91(6):534–545. doi: 10.1111/ejh.12187
   PubMed Web of Science ®Google Scholar
• Sarva H, Graber J, Remanan R, et al. CMV encephalitis in BMT recipients. Bone Marrow Transplant. 2012;47(2):318–320. doi: 10.1038/bmt.2011.80
   PubMed Web of Science ®Google Scholar
• Quinnan GJ, Kirmani N, Rook AH, et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982;307(1):7–13. doi: 10.1056/NEJM198207013070102
   PubMed Web of Science ®Google Scholar
• Reusser P, Riddell SR, Meyers JD, et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78(5):1373–1380. doi: 10.1182/blood.V78.5.1373.1373
   PubMed Web of Science ®Google Scholar
• Comoli P, Maccario R, Locatelli F, et al. Adoptive transfer of herpesvirusspecific cytotoxic t lymphocytes in transplant recipients. Herpes. 2000;7(1):9–12.
   PubMedGoogle Scholar
• Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–1166. doi: 10.1038/nm1475
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362(9393):1375–1377. doi: 10.1016/S0140-6736(03)14634-X
   PubMed Web of Science ®Google Scholar
• Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–241. doi: 10.1126/science.1352912
   PubMed Web of Science ®Google Scholar
• Bao L, Cowan M J, Dunham K, et al. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother. 2012;35(3):293–298. doi: 10.1097/CJI.0b013e31824300a2
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916–3922. doi: 10.1182/blood.V99.11.3916
   PubMed Web of Science ®Google Scholar
• Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(6):707–714. doi: 10.1016/j.bbmt.2007.02.004
   PubMed Web of Science ®Google Scholar
• Aubert G, Hassan-Walker AF, Madrigal JA, et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis. 2001;184(8):955–963. doi: 10.1086/323354
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97(5):1232–1240. doi: 10.1182/blood.V97.5.1232
   PubMed Web of Science ®Google Scholar
• Engstrand M, Lidehall AK, Totterman TH, et al. Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment. Clin Exp Immunol. 2003;132(1):96–104. doi: 10.1046/j.1365-2249.2003.02098.x
   PubMed Web of Science ®Google Scholar